FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 613 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... June 13, 2025 A new target to slow down ageing and reduce blood cancer... June 29, 2023 GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence... July 13, 2026 Load more HOT NEWS Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... Advancing Patient Care Through Focused Innovation Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer Olaparib approved for 800 prostate and breast cancer patients in England
